Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, Portengen H, Foekens JA

British journal of cancer1 Oct 1990Cited by 62 (Europe PMC)

PMID1977468PMCIDPMC1971491DOI10.1038/bjc.1990.343PepBankPUB-01977468

Summary

Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of experimental pancreatic tumours. Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995). All patients had an extensive tumour load and 13 were pretreated with chemotherapy. Before Sandostatin treatment the patients with pancreatic cancer showed a higher mean plasma concentration of GH (P less than 0.05) and a lower concentration of 'total' somatomedin-C (P less than 0.005) compared with patients with colorectal cancer; there was no significant difference between these two groups in plasma levels of directly assayable somatomedin-C, EGF/TGF-alpha, insulin and prolactin. Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks. Plasma insulin levels also were suppressed but only during the first 3-5 days of treatment. Plasma EGF-TGF-alpha levels increased significantly at day 5 of treatment only in the pancreatic cancer patients. Twenty-seven per cent of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects. However, the overall survival remained disappointing, emphasising the need for better treatment regimens.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In metastatic pancreatic and gastrointestinal cancer patients receiving octreotide, 27% had stable disease for 3-9 months.
In plain wordsIn metastatic pancreatic and gastrointestinal cancer patients receiving octreotide, 27% had stable disease for 3-9 months.
Peptide
Octreotide
Outcome
Not applicableStable disease
Study
n = 34
Outcome group
Tumor growth · Cancer
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Measurements
Patients with stable disease
27%
metastatic pancreatic, colorectal and gastric cancer
Duration of stable disease
3 to 9 months
patients with stable disease
Source sentences
Summary
Twenty-seven per cent of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746806
02HumanNon-randomized trialEfficacy outcome
In metastatic pancreatic cancer patients, plasma EGF-TGF-alpha increased significantly at day 5 of octreotide treatment.
In plain wordsIn metastatic pancreatic cancer patients, EGF-TGF-alpha increased from pretreatment at day 5 of octreotide treatment.
Peptide
Octreotide
Outcome
IncreasePancreatic cancer EGF-TGF-alpha
Study
n = 14
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Plasma EGF-TGF-alpha levels increased significantly at day 5 of treatment only in the pancreatic cancer patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746805
03HumanNon-randomized trialEfficacy outcome
In metastatic gastrointestinal cancer patients, somatomedin-C initially decreased within 3 days after octreotide treatment began.
In plain wordsIn metastatic gastrointestinal cancer patients, somatomedin-C decreased from pretreatment within 3 days after octreotide began.
Peptide
Octreotide
Outcome
DecreaseInitial somatomedin-C decrease
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746801
04HumanNon-randomized trialEfficacy outcome
In metastatic gastrointestinal cancer patients, basal GH did not change during the initial somatomedin-C decrease after octreotide began.
In plain wordsIn metastatic gastrointestinal cancer patients, basal growth hormone did not change during the early response to octreotide.
Peptide
Octreotide
Outcome
No significant changeBasal GH
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746802
05HumanNon-randomized trialEfficacy outcome
In metastatic gastrointestinal cancer patients receiving octreotide, somatomedin-C returned to pretreatment levels within 4-13 weeks.
In plain wordsIn metastatic gastrointestinal cancer patients receiving octreotide, somatomedin-C returned to pretreatment levels within 4-13 weeks.
Peptide
Octreotide
Outcome
No significant changeLater somatomedin-C levels
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746803
06HumanNon-randomized trialEfficacy outcome
In metastatic gastrointestinal cancer patients, octreotide suppressed plasma insulin only during the first 3-5 days of treatment.
In plain wordsIn metastatic gastrointestinal cancer patients, octreotide suppressed insulin from pretreatment only during the first 3-5 days.
Peptide
Octreotide
Outcome
DecreaseEarly plasma insulin suppression
Study
n: not reported in source
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Plasma insulin levels also were suppressed but only during the first 3-5 days of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746804
07HumanNon-randomized trialEfficacy outcome
Most metastatic pancreatic and gastrointestinal cancer patients experienced subjective improvement during octreotide treatment.
In plain wordsMost metastatic pancreatic and gastrointestinal cancer patients reported improvement during octreotide treatment.
Peptide
Octreotide
Outcome
Direction not reportedSubjective improvement
Study
n: not reported in source
Outcome group
Subjective improvement · Whole body
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Twenty-seven per cent of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746807
08HumanNon-randomized trialSafety outcome
In metastatic pancreatic and gastrointestinal cancer patients, octreotide treatment occurred without serious side effects.
In plain wordsIn metastatic pancreatic and gastrointestinal cancer patients, investigators reported no serious side effects during octreotide treatment.
Peptide
Octreotide
Outcome
Not applicableSerious side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
100-200 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Twenty-seven per cent of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995).
Summary · context
All patients had an extensive tumour load and 13 were pretreated with chemotherapy.
Show in the study text Report a problemFND-0197746808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.